The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
20210195: Clearlake Capital Partners V, L.P.; TractManager Holdings, LLC
20210233: Arch Capital Group Ltd.; Watford Holdings Ltd.
20210238: Francisco Partners V, L.P.; Kevin A. Plank
20210241: Hexagon AB; Eddie Habibi
20210242: GI Partners Fund VI LP; Ares Corporate Opportunities Fund IV, L.P.
20210243: Vista Equity Partners Fund V, L.P.; Information Builders, Inc.
20210244: Centerbridge Capital Partners III, L.P.; Syncapay, Inc.
20210246: Waterfall EIT Cayman LP; Alternative Credit Investments plc
20210247: Centerbridge Capital Partners III, L.P.; Wirecard AG
20210248: Repligen Corporation; Michael Gagne
20210249: Marcelo Camberos; KarpReilly Capital Partners III, L.P.
20210252: Paul & Sandra Edgerley; Ross Vogt
20210253: CP VII Evolution Holdings, L.P.; North Haven MP Topco, LLC
20210257: Berkshire Fund IX, L.P.; Paine Schwartz Food Chain Fund IV, L.P.
20210258: Ocado Group plc; Kindred Systems Inc.
20210259: Vistria Fund III, LP; TVG Bolt Holdings, LLC
20210261: London Stock Exchange Group plc; Tritium I, LP
Kushly, LLC
In May 2021, The FTC announced a law enforcement action to halt deceptive health and efficacy claims in the growing market for cannabidiol (CBD) products. In the action—the first since the Commission announced a crackdown on such false claims last December—Scottsdale, Arizona-based Kushly Industries LLC (Kushly) and the company’s sole officer Cody Alt agreed not to make false or unsupported claims or falsely claim that scientific evidence exists to back them up. They also paid the FTC more than $30,000 in consumer redress.